CA
NZ
UK
AU
IND
US
Phathom Pharmaceuticals, Inc. showcased a Q2 2026 earnings per share (EPS) of $-0.21, falling short of analysts' expectations, which pegged the figure at $-0.26. This underperformance erodes investor confidence, especially amid a significant drop in the stock’s value. The earnings miss illustrates the potential …
Quince Therapeutics, Inc. (NASDAQ: QNCX) is demonstrating signs of recovery, recently showing a 26.6% rise in share price over the past month. This surge is particularly noteworthy given the stark backdrop of a staggering 96.2% decline year-to-date. The company’s current market capitalization is approximately …
Regeneron Pharmaceuticals (NASDAQ: REGN) posted a strong second‑quarter performance, delivering adjusted earnings of $14.29 per diluted share and total revenue of $4.291 billion, reflecting a 17% year‑over‑year increase. The earnings uplift was driven primarily by strong sales of Dupixent.
Replimune (NASDAQ: REPL) announced that the FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee expressed majority support for its RP1 oncolytic virus combined with nivolumab in the treatment of advanced melanoma. The panel concluded that the IGNYTE study results are both evaluable and clinically …
Tempus AI, Inc. posted revenue of $382.5 million for Q2 2026, a 22% year-over-year increase, while net income reached $5.6 million. This positive performance enabled the company to raise its 2026 revenue guidance, reflecting strong growth in oncology diagnostics.Key HighlightsEPS came in at $-0.13, …
Revenue Growth Outpaces Expectations
Neurocrine Biosciences (NASDAQ: NBIX) posted second‑quarter revenue of $959 million, a 39% increase from the comparable period last year, while earnings per share advanced to $1.39, beating the consensus outlook. The results highlight the continued strength of INGREZZA and the contribution of newly integrated …
Omnicell, Inc. (NASDAQ: OMCL) delivered a solid financial performance for the second quarter of 2026, posting revenues of $312 million. This amount represents an increase of $22 million, or roughly 7 % compared with the same quarter a year earlier, underscoring continued momentum in …
Myriad Genetics, Inc. (NASDAQ: MYGN) reported a substantial loss of $-0.25 per share for the second quarter ended June 30, 2026, falling short of the consensus estimate of $-0.06. Despite maintaining a solid operational performance, the company's revenue saw a significant decrease of 11% …
NEOGEN Corp. (NASDAQ: NEOG) reported a net loss of $11.3 million in its fiscal fourth quarter ending June 30, marking a significant contrast to the previous year’s quarter when losses were substantially higher. The company’s revenue remained relatively stable at $225.3 million, a slight …
Please wait processing your request...